This story has been updated to include comments from advisory firm Glass Lewis.

NEW YORK (GenomeWeb) – Investment firm Lone Star Value Management has issued an open letter to all Enzo Biochem shareholders, urging them to vote for two Lone Star nominees to Enzo's board of directors.

In the letter published Tuesday, Lone Star said it has "serious concerns" with Enzo's "poor performance and disregard for shareholder rights."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.